Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
Shan Su, Weihua Li, Shibo Jiang
Trends in Immunology (2022) Vol. 43, Iss. 3, pp. 170-172
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
Shuai Xia, Lijue Wang, Yun Zhu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 134
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
John P. Evans, Cong Zeng, Panke Qu, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1093-1102.e3
Open Access | Times Cited: 128
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
Panke Qu, John P. Evans, Julia N. Faraone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 80
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 67
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 44
A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages
Xiantao Zhang, Shijian Wu, Jie Liu, et al.
Advanced Science (2023) Vol. 10, Iss. 27
Open Access | Times Cited: 25
Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic
Esther Dawen Yu, Tara M. Narowski, Eric Wang, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 9, pp. 1269-1278.e4
Open Access | Times Cited: 29
Sustained exposure to multivalent antigen-decorated nanoparticles generates broad anti-coronavirus responses
Julie Baillet, John H. Klich, Ben S. Ou, et al.
Matter (2025), pp. 102006-102006
Open Access
Derivatives of MOPS: promising scaffolds for SARS coronaviruses Macro domain‐targeted inhibition
Oney Ortega Granda, Karine Alvarez, Benjamin Morin, et al.
FEBS Journal (2025)
Open Access
Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
Qiaoshuai Lan, Lijue Wang, Fanke Jiao, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 22
Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence
David J. Bean, Janet Monroe, Yan Mei Liang, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 751
Open Access | Times Cited: 4
Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
Jie Zhou, Zezhong Liu, Guangxu Zhang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 21
Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
Abdul Aziz Al-Fattah Bin Yahaya, Kanwal Khalid, Hui Xuan Lim, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 624-624
Open Access | Times Cited: 10
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
Qiaoshuai Lan, Jasper Fuk‐Woo Chan, Wei Xu, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 549-549
Open Access | Times Cited: 16
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
Xinling Wang, Lujia Sun, Zezhong Liu, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
Zhongcheng Zhou, Peng Du, Ning Li, et al.
MedComm (2022) Vol. 3, Iss. 2
Open Access | Times Cited: 14
The Immunogenicity of CpG, MF59-Like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice
Kangwei Xu, Jing Li, Lu Xu, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 60-60
Open Access | Times Cited: 2
Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion
Kristen A. Rodrigues, Yiming Zhang, Aereas Aung, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP
Parisa Yousefpour, Yiming Zhang, Laura Maiorino, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
Pradeep Darshana Pushpakumara, Chandima Jeewandara, Farha Bary, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Novel mechanism of the COVID-19 associated coagulopathy (CAC) and vascular thromboembolism
Mahavir Singh, Sathnur Pushpakumar, Yuting Zheng, et al.
npj Viruses (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 6
Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
Pradeep Darshana Pushpakumara, Chandima Jeewandara, Farha Bary, et al.
Clinical & Experimental Immunology (2023) Vol. 215, Iss. 3, pp. 268-278
Open Access | Times Cited: 3
Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants
Yan Wu, Jian Shi, Xiaoxue He, et al.
Journal of Virology (2023) Vol. 97, Iss. 11
Open Access | Times Cited: 3
Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens
Matheus Oliveira de Souza, Bharat Madan, I‐Ting Teng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 5
Clinical development of antivirals against SARS-CoV-2 and its variants
Qiaoshuai Lan, Yan Yan, Guangxu Zhang, et al.
Current Research in Microbial Sciences (2023) Vol. 6, pp. 100208-100208
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top